Industry Strength Score
32/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
IMMATICS NV (IMTX) Stock Price & Overview
NASDAQ:IMTX • NL0015285941
Current stock price
10.79 USD
-0.2 (-1.82%)
At close:
10.71 USD
-0.08 (-0.74%)
Pre-Market:
The current stock price of IMTX is 10.79 USD. Today IMTX is down by -1.82%. In the past month the price increased by 4.25%. In the past year, price increased by 106.31%.
IMTX Key Statistics
52-Week Range3.94 - 12.41
Current IMTX stock price positioned within its 52-week range.
1-Month Range9.92 - 11.65
Current IMTX stock price positioned within its 1-month range.
- Market Cap
- 1.447B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.90
- Dividend Yield
- N/A
IMTX Stock Performance
Today
-1.82%
1 Week
-4.93%
1 Month
+4.25%
3 Months
+12.98%
Longer-term
6 Months +5.89%
1 Year +106.31%
2 Years -2.18%
3 Years +9.32%
5 Years -3.92%
10 Years N/A
IMTX Stock Chart
IMTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IMTX. When comparing the yearly performance of all stocks, IMTX is one of the better performing stocks in the market, outperforming 91.63% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
IMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMTX. While IMTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IMTX Earnings
On March 5, 2026 IMTX reported an EPS of -0.29 and a revenue of 19.76M. The company beat EPS expectations (24.43% surprise) and beat revenue expectations (100.11% surprise).
Next Earnings DateMay 11, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-€0.29
Revenue Reported19.761M
EPS Surprise 24.43%
Revenue Surprise 100.11%
IMTX Forecast & Estimates
17 analysts have analysed IMTX and the average price target is 18.87 USD. This implies a price increase of 74.88% is expected in the next year compared to the current price of 10.79.
For the next year, analysts expect an EPS growth of 1.4% and a revenue growth 17.63% for IMTX
Analysts
Analysts87.06
Price Target18.87 (74.88%)
EPS Next Y1.4%
Revenue Next Year17.63%
IMTX Financial Highlights
Over the last trailing twelve months IMTX reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS decreased by -1180% compared to the year before.
Income Statements
Revenue(TTM)48.27M
Net Income(TTM)-196.45M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.93% | ||
| ROE | -40.58% | ||
| Debt/Equity | 0.03 |
Chartmill High Growth Momentum
EPS Q2Q%-167.44%
Sales Q2Q%-64.87%
EPS 1Y (TTM)-1180%
Revenue 1Y (TTM)-69.03%
IMTX Ownership
Ownership
Inst Owners68.64%
Shares134.10M
Float99.67M
Ins Owners5.09%
Short Float %5.15%
Short Ratio11.43
IMTX Industry Overview
IMTX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 51 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
77/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
16%
Outperformed 16% of sub-industries
3 Month Rank
19%
Outperformed 19% of sub-industries
6 Month Rank
36%
Outperformed 36% of sub-industries
Industry Fundamentals & Breadth
- Members
- 51
- New Highs
- 2%
- New Lows
- 11.8%
- Average ROE
- 26.9%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 26.1%
- Average P/E
- 38.5
- Average Fwd P/E
- 30.5
- Average Debt/Equity
- 0.0
IMTX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.53 | 365.426B | ||
| AMGN | AMGEN INC | 13.77 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.63 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 26.24 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.4 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.43 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMTX
Company Profile
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 285 full-time employees. The company went IPO on 2020-07-02. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Company Info
IPO: 2020-07-02
IMMATICS NV
Paul Ehrlich-Strasse 15
Tuebingen BADEN-WUERTTEMBERG 72076 DE
CEO: Harpreet Singh
Employees: 285
Phone: 4970715397700
IMMATICS NV / IMTX FAQ
What does IMTX do?
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 285 full-time employees. The company went IPO on 2020-07-02. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Can you provide the latest stock price for IMMATICS NV?
The current stock price of IMTX is 10.79 USD. The price decreased by -1.82% in the last trading session.
Does IMMATICS NV pay dividends?
IMTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMTX stock?
IMTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is IMMATICS NV (IMTX) stock traded?
IMTX stock is listed on the Nasdaq exchange.
What is IMMATICS NV worth?
IMMATICS NV (IMTX) has a market capitalization of 1.45B USD. This makes IMTX a Small Cap stock.
Can you provide the upcoming earnings date for IMMATICS NV?
IMMATICS NV (IMTX) will report earnings on 2026-05-11.